These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff. Gallichotte EN; Nehring M; Stromberg S; Young MC; Snell A; Daniels J; Pabilonia KL; VandeWoude S; Ehrhart N; Ebel GD mSphere; 2022 Aug; 7(4):e0016922. PubMed ID: 35862798 [TBL] [Abstract][Full Text] [Related]
27. Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines. Wang J; Huang L; Guo N; Yao YP; Zhang C; Xu R; Jiao YM; Li YQ; Song YR; Wang FS; Fan X Viruses; 2023 Apr; 15(4):. PubMed ID: 37112897 [TBL] [Abstract][Full Text] [Related]
28. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G Front Immunol; 2022; 13():863554. PubMed ID: 35711445 [TBL] [Abstract][Full Text] [Related]
29. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV. Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335 [TBL] [Abstract][Full Text] [Related]
30. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956 [TBL] [Abstract][Full Text] [Related]
32. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724 [TBL] [Abstract][Full Text] [Related]
33. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. Garcia L; Woudenberg T; Rosado J; Dyer AH; Donnadieu F; Planas D; Bruel T; Schwartz O; Prazuck T; Velay A; Fafi-Kremer S; Batten I; Reddy C; Connolly E; McElheron M; Kennelly SP; Bourke NM; White MT; Pelleau S Viruses; 2022 Jul; 14(7):. PubMed ID: 35891471 [TBL] [Abstract][Full Text] [Related]
34. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2022; 13():995235. PubMed ID: 36172368 [TBL] [Abstract][Full Text] [Related]
35. Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern. Kumar NP; Banurekha VV; Kumar CPG; Nancy A; Padmapriyadarsini C; Shankar S; Hanna LE; Murhekar M; Devi KRU; Babu S J Travel Med; 2022 Sep; 29(6):. PubMed ID: 35900009 [TBL] [Abstract][Full Text] [Related]
36. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD; Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504 [TBL] [Abstract][Full Text] [Related]
37. Cross-Reactive Antibody Responses to Coronaviruses Elicited by SARS-CoV-2 Infection or Vaccination. Lee RSH; Cheng SMS; Zhao J; Tsoi AYS; Lau KKM; Chan CHC; Li JKC; Hui DSC; Peiris M; Yen HL Influenza Other Respir Viruses; 2024 May; 18(5):e13309. PubMed ID: 38725111 [TBL] [Abstract][Full Text] [Related]
38. Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines. Yi X; Wang Y; Li Q; Li X; Zhang P; Fu X; Gu S; Zhang D; Liu X; Lou H; Wu Y; Tang L; Hou J; Li Y J Med Virol; 2023 Mar; 95(3):e28642. PubMed ID: 36890630 [TBL] [Abstract][Full Text] [Related]